The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
Introduction: The purpose of the present study was to investigate the relationship of expression of hypoxia inducible factor (HIF)-1α-modifying enzymes prolyl hydroxylase (PHD)1, PHD2 and PHD3 to response of tumours and survival in breast cancer patients enrolled in a phase II trial of neoadjuvant a...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797053340725542912 |
|---|---|
| author | Fox, S Generali, D Berruti, A Brizzi, M Campo, L Bonardi, S Bersiga, A Allevi, G Milani, M Aguggini, S Mele, T Dogliotti, L Bottini, A Harris, A |
| author_facet | Fox, S Generali, D Berruti, A Brizzi, M Campo, L Bonardi, S Bersiga, A Allevi, G Milani, M Aguggini, S Mele, T Dogliotti, L Bottini, A Harris, A |
| author_sort | Fox, S |
| collection | OXFORD |
| description | Introduction: The purpose of the present study was to investigate the relationship of expression of hypoxia inducible factor (HIF)-1α-modifying enzymes prolyl hydroxylase (PHD)1, PHD2 and PHD3 to response of tumours and survival in breast cancer patients enrolled in a phase II trial of neoadjuvant anthracycline and tamoxifen therapy.Methods: The expression of PHD1, PHD2 and PHD3 together with HIF-1α and the HIF-inducible genes vascular endothelial cell growth factor (VEGF) and carbonic anhydrase IX were assessed by immunohistochemistry using a tissue microarray approach in 211 patients with T2-4 N0-1 breast cancer enrolled in a randomised trial comparing single-agent epirubicin versus epirubicin and tamoxifen as the primary systemic treatment.Results: PHD1, PHD2 and PHD3 were detected in 47/179 (26.7%), 85/163 (52.2%) and 69/177 (39%) of tumours at baseline. PHD2 and PHD3 expression was moderate/strong whereas PHD1 expression was generally weak. There was a significant positive correlation between HIF-1α and PHD1 (P = 0.002) and PHD3 (P < 0.05) but not PHD2 (P = 0.41). There was a significant positive relationship between VEGF and PHD1 (P < 0.008) and PHD3 (P = 0.001) but not PHD2 (P = 0.09). PHD1, PHD2 and PHD3 expression was significantly increased after epirubicin therapy (all P < 0.000) with no significant difference in PHD changes between the treatment arms. There was no significant difference in response in tumours that expressed PHDs and PHD expression was not associated with survival.Conclusions: Although expression of the PHDs was not related to response or survival in patients receiving neoadjuvant epirubicin, our data provide the first evidence that these enzymes are upregulated on therapy in breast cancer and that the biological effects independent of HIF make them therapeutic targets. © 2011 Fox et al.; licensee BioMed Central Ltd. |
| first_indexed | 2024-03-06T18:42:28Z |
| format | Journal article |
| id | oxford-uuid:0d5bd5e9-b6df-4dfb-a537-3b696277a769 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:42:28Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:0d5bd5e9-b6df-4dfb-a537-3b696277a7692022-03-26T09:40:06ZThe prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifenJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0d5bd5e9-b6df-4dfb-a537-3b696277a769EnglishSymplectic Elements at Oxford2011Fox, SGenerali, DBerruti, ABrizzi, MCampo, LBonardi, SBersiga, AAllevi, GMilani, MAguggini, SMele, TDogliotti, LBottini, AHarris, AIntroduction: The purpose of the present study was to investigate the relationship of expression of hypoxia inducible factor (HIF)-1α-modifying enzymes prolyl hydroxylase (PHD)1, PHD2 and PHD3 to response of tumours and survival in breast cancer patients enrolled in a phase II trial of neoadjuvant anthracycline and tamoxifen therapy.Methods: The expression of PHD1, PHD2 and PHD3 together with HIF-1α and the HIF-inducible genes vascular endothelial cell growth factor (VEGF) and carbonic anhydrase IX were assessed by immunohistochemistry using a tissue microarray approach in 211 patients with T2-4 N0-1 breast cancer enrolled in a randomised trial comparing single-agent epirubicin versus epirubicin and tamoxifen as the primary systemic treatment.Results: PHD1, PHD2 and PHD3 were detected in 47/179 (26.7%), 85/163 (52.2%) and 69/177 (39%) of tumours at baseline. PHD2 and PHD3 expression was moderate/strong whereas PHD1 expression was generally weak. There was a significant positive correlation between HIF-1α and PHD1 (P = 0.002) and PHD3 (P < 0.05) but not PHD2 (P = 0.41). There was a significant positive relationship between VEGF and PHD1 (P < 0.008) and PHD3 (P = 0.001) but not PHD2 (P = 0.09). PHD1, PHD2 and PHD3 expression was significantly increased after epirubicin therapy (all P < 0.000) with no significant difference in PHD changes between the treatment arms. There was no significant difference in response in tumours that expressed PHDs and PHD expression was not associated with survival.Conclusions: Although expression of the PHDs was not related to response or survival in patients receiving neoadjuvant epirubicin, our data provide the first evidence that these enzymes are upregulated on therapy in breast cancer and that the biological effects independent of HIF make them therapeutic targets. © 2011 Fox et al.; licensee BioMed Central Ltd. |
| spellingShingle | Fox, S Generali, D Berruti, A Brizzi, M Campo, L Bonardi, S Bersiga, A Allevi, G Milani, M Aguggini, S Mele, T Dogliotti, L Bottini, A Harris, A The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| title | The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| title_full | The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| title_fullStr | The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| title_full_unstemmed | The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| title_short | The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| title_sort | prolyl hydroxylase enzymes are positively associated with hypoxia inducible factor 1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen |
| work_keys_str_mv | AT foxs theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT generalid theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT berrutia theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT brizzim theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT campol theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT bonardis theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT bersigaa theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT allevig theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT milanim theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT agugginis theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT melet theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT dogliottil theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT bottinia theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT harrisa theprolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT foxs prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT generalid prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT berrutia prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT brizzim prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT campol prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT bonardis prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT bersigaa prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT allevig prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT milanim prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT agugginis prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT melet prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT dogliottil prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT bottinia prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen AT harrisa prolylhydroxylaseenzymesarepositivelyassociatedwithhypoxiainduciblefactor1aandvascularendothelialgrowthfactorinhumanbreastcancerandalterinresponsetoprimarysystemictreatmentwithepirubicinandtamoxifen |